Pradaxa dabigatran etexilate: Phase III started

Boehringer began the open-label, international Phase III RE-DUAL PCI trial to compare 110 or 150 mg oral Pradaxa twice daily plus clopidogrel or ticagrelor vs. triple antithrombotic therapy comprising warfarin, aspirin and either clopidogrel or ticagrelor in up to 8,500 patients. Boehringer is conducting the trial with Harvard Clinical Research Institute. RE-DUAL PCI is part of Boehringer’s RE-VOLUTION clinical trial program, which will include 15 trials and over 60,000 patients. ...